Hmdb loader
Record Information
Version5.0
StatusExpected but not Quantified
Creation Date2012-09-06 15:16:52 UTC
Update Date2022-03-07 02:52:04 UTC
HMDB IDHMDB0015678
Secondary Accession Numbers
  • HMDB15678
Metabolite Identification
Common NameNepafenac
DescriptionNepafenac, also known as nevanac or ahr 9434, belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups. After penetrating the cornea as a prodrug, nepafenac undergoes rapid bioactivation to amfenac, which is a potent NSAID that uniformly inhibits the COX1 and COX2 activity. Nepafenac (prodrug) is deaminated to amfenac (active compound) in the ciliary body epithelium, retina, and choroid by intraocular hydrolases. Nepafenac is a drug which is used for the treatment of pain and inflammation associated with cataract surgery. Ocularly applied non-steroidal anti-inflammatory drugs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. It is used to treat pain and inflammation associated with cataract surgery. The mean steady-state Cmax for nepafenac and for amfenac were 0.310 ± 0.104 ng/ml and 0.422 ± 0.121 ng/ml, respectively, following ocular administration. Nepafenac is a moderately basic compound (based on its pKa). In humans, nepafenac is involved in nepafenac action pathway. Nepafenac is only found in individuals that have used or taken this drug. Subsequently, amfenac undergoes extensive metabolism to more polar metabolites involving hydroxylation of the aromatic ring leading to glucuronide conjugate formation.
Structure
Data?1582753322
Synonyms
ValueSource
2-Amino-3-benzoylbenzeneacetamideChEBI
AHR 9434ChEBI
AHR-9434ChEBI
AL 6515ChEBI
AL-6515ChEBI
NepafenacoChEBI
NepafenacumChEBI
NevanacChEBI
Amfenac amideHMDB
Chemical FormulaC15H14N2O2
Average Molecular Weight254.2839
Monoisotopic Molecular Weight254.105527702
IUPAC Name2-(2-amino-3-benzoylphenyl)acetamide
Traditional Namenepafenac
CAS Registry Number78281-72-8
SMILES
NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N
InChI Identifier
InChI=1S/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18)
InChI KeyQEFAQIPZVLVERP-UHFFFAOYSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzophenones
Direct ParentBenzophenones
Alternative Parents
Substituents
  • Benzophenone
  • Aryl-phenylketone
  • Diphenylmethane
  • Phenylacetamide
  • Benzoyl
  • Aniline or substituted anilines
  • Aryl ketone
  • Vinylogous amide
  • Amino acid or derivatives
  • Carboxamide group
  • Primary carboxylic acid amide
  • Ketone
  • Carboxylic acid derivative
  • Amine
  • Organonitrogen compound
  • Organooxygen compound
  • Primary amine
  • Hydrocarbon derivative
  • Organic oxide
  • Carbonyl group
  • Organopnictogen compound
  • Organic oxygen compound
  • Organic nitrogen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Ontology
Physiological effectNot Available
Disposition
Process
RoleNot Available
Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
Water Solubility0.02 g/LALOGPS
logP1.53ALOGPS
logP2.08ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)15.82ChemAxon
pKa (Strongest Basic)1.83ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area86.18 ŲChemAxon
Rotatable Bond Count4ChemAxon
Refractivity74.46 m³·mol⁻¹ChemAxon
Polarizability26.63 ųChemAxon
Number of Rings2ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DarkChem[M+H]+160.05731661259
DarkChem[M-H]-158.11531661259
DeepCCS[M+H]+158.48230932474
DeepCCS[M-H]-156.12430932474
DeepCCS[M-2H]-189.35630932474
DeepCCS[M+Na]+164.57530932474
AllCCS[M+H]+159.132859911
AllCCS[M+H-H2O]+155.332859911
AllCCS[M+NH4]+162.732859911
AllCCS[M+Na]+163.832859911
AllCCS[M-H]-161.232859911
AllCCS[M+Na-2H]-161.032859911
AllCCS[M+HCOO]-160.932859911

Predicted Retention Times

Underivatized

Chromatographic MethodRetention TimeReference
Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022.4.52 minutes32390414
Predicted by Siyang on May 30, 202211.7824 minutes33406817
Predicted by Siyang using ReTip algorithm on June 8, 20221.87 minutes32390414
AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid35.4 seconds40023050
Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid1605.6 seconds40023050
Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid311.2 seconds40023050
Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid138.3 seconds40023050
Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid188.0 seconds40023050
RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid103.0 seconds40023050
Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid379.1 seconds40023050
BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid453.0 seconds40023050
HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate)128.5 seconds40023050
UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid983.6 seconds40023050
BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid372.9 seconds40023050
UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid1137.1 seconds40023050
SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid307.3 seconds40023050
RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid340.0 seconds40023050
MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate301.4 seconds40023050
KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA310.6 seconds40023050
Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water92.0 seconds40023050

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
NepafenacNC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N4024.5Standard polar33892256
NepafenacNC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N2501.2Standard non polar33892256
NepafenacNC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N2699.6Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Nepafenac,1TMS,isomer #1C[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N2521.5Semi standard non polar33892256
Nepafenac,1TMS,isomer #1C[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N2614.2Standard non polar33892256
Nepafenac,1TMS,isomer #1C[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N3483.4Standard polar33892256
Nepafenac,1TMS,isomer #2C[Si](C)(C)NC1=C(CC(N)=O)C=CC=C1C(=O)C1=CC=CC=C12529.4Semi standard non polar33892256
Nepafenac,1TMS,isomer #2C[Si](C)(C)NC1=C(CC(N)=O)C=CC=C1C(=O)C1=CC=CC=C12492.6Standard non polar33892256
Nepafenac,1TMS,isomer #2C[Si](C)(C)NC1=C(CC(N)=O)C=CC=C1C(=O)C1=CC=CC=C13444.3Standard polar33892256
Nepafenac,2TMS,isomer #1C[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N[Si](C)(C)C2553.5Semi standard non polar33892256
Nepafenac,2TMS,isomer #1C[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N[Si](C)(C)C2634.7Standard non polar33892256
Nepafenac,2TMS,isomer #1C[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N[Si](C)(C)C3089.1Standard polar33892256
Nepafenac,2TMS,isomer #2C[Si](C)(C)N(C(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N)[Si](C)(C)C2579.6Semi standard non polar33892256
Nepafenac,2TMS,isomer #2C[Si](C)(C)N(C(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N)[Si](C)(C)C2676.5Standard non polar33892256
Nepafenac,2TMS,isomer #2C[Si](C)(C)N(C(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N)[Si](C)(C)C3359.2Standard polar33892256
Nepafenac,2TMS,isomer #3C[Si](C)(C)N(C1=C(CC(N)=O)C=CC=C1C(=O)C1=CC=CC=C1)[Si](C)(C)C2529.4Semi standard non polar33892256
Nepafenac,2TMS,isomer #3C[Si](C)(C)N(C1=C(CC(N)=O)C=CC=C1C(=O)C1=CC=CC=C1)[Si](C)(C)C2538.5Standard non polar33892256
Nepafenac,2TMS,isomer #3C[Si](C)(C)N(C1=C(CC(N)=O)C=CC=C1C(=O)C1=CC=CC=C1)[Si](C)(C)C3262.3Standard polar33892256
Nepafenac,3TMS,isomer #1C[Si](C)(C)NC1=C(CC(=O)N([Si](C)(C)C)[Si](C)(C)C)C=CC=C1C(=O)C1=CC=CC=C12631.8Semi standard non polar33892256
Nepafenac,3TMS,isomer #1C[Si](C)(C)NC1=C(CC(=O)N([Si](C)(C)C)[Si](C)(C)C)C=CC=C1C(=O)C1=CC=CC=C12700.4Standard non polar33892256
Nepafenac,3TMS,isomer #1C[Si](C)(C)NC1=C(CC(=O)N([Si](C)(C)C)[Si](C)(C)C)C=CC=C1C(=O)C1=CC=CC=C12980.6Standard polar33892256
Nepafenac,3TMS,isomer #2C[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N([Si](C)(C)C)[Si](C)(C)C2563.2Semi standard non polar33892256
Nepafenac,3TMS,isomer #2C[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N([Si](C)(C)C)[Si](C)(C)C2585.5Standard non polar33892256
Nepafenac,3TMS,isomer #2C[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N([Si](C)(C)C)[Si](C)(C)C2906.3Standard polar33892256
Nepafenac,4TMS,isomer #1C[Si](C)(C)N(C(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N([Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C2641.7Semi standard non polar33892256
Nepafenac,4TMS,isomer #1C[Si](C)(C)N(C(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N([Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C2720.9Standard non polar33892256
Nepafenac,4TMS,isomer #1C[Si](C)(C)N(C(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N([Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C2809.1Standard polar33892256
Nepafenac,1TBDMS,isomer #1CC(C)(C)[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N2726.8Semi standard non polar33892256
Nepafenac,1TBDMS,isomer #1CC(C)(C)[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N2805.7Standard non polar33892256
Nepafenac,1TBDMS,isomer #1CC(C)(C)[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N3523.1Standard polar33892256
Nepafenac,1TBDMS,isomer #2CC(C)(C)[Si](C)(C)NC1=C(CC(N)=O)C=CC=C1C(=O)C1=CC=CC=C12748.6Semi standard non polar33892256
Nepafenac,1TBDMS,isomer #2CC(C)(C)[Si](C)(C)NC1=C(CC(N)=O)C=CC=C1C(=O)C1=CC=CC=C12713.9Standard non polar33892256
Nepafenac,1TBDMS,isomer #2CC(C)(C)[Si](C)(C)NC1=C(CC(N)=O)C=CC=C1C(=O)C1=CC=CC=C13519.9Standard polar33892256
Nepafenac,2TBDMS,isomer #1CC(C)(C)[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N[Si](C)(C)C(C)(C)C2961.4Semi standard non polar33892256
Nepafenac,2TBDMS,isomer #1CC(C)(C)[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N[Si](C)(C)C(C)(C)C3024.6Standard non polar33892256
Nepafenac,2TBDMS,isomer #1CC(C)(C)[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N[Si](C)(C)C(C)(C)C3263.5Standard polar33892256
Nepafenac,2TBDMS,isomer #2CC(C)(C)[Si](C)(C)N(C(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N)[Si](C)(C)C(C)(C)C3012.2Semi standard non polar33892256
Nepafenac,2TBDMS,isomer #2CC(C)(C)[Si](C)(C)N(C(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N)[Si](C)(C)C(C)(C)C3078.7Standard non polar33892256
Nepafenac,2TBDMS,isomer #2CC(C)(C)[Si](C)(C)N(C(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N)[Si](C)(C)C(C)(C)C3398.9Standard polar33892256
Nepafenac,2TBDMS,isomer #3CC(C)(C)[Si](C)(C)N(C1=C(CC(N)=O)C=CC=C1C(=O)C1=CC=CC=C1)[Si](C)(C)C(C)(C)C2979.8Semi standard non polar33892256
Nepafenac,2TBDMS,isomer #3CC(C)(C)[Si](C)(C)N(C1=C(CC(N)=O)C=CC=C1C(=O)C1=CC=CC=C1)[Si](C)(C)C(C)(C)C2930.4Standard non polar33892256
Nepafenac,2TBDMS,isomer #3CC(C)(C)[Si](C)(C)N(C1=C(CC(N)=O)C=CC=C1C(=O)C1=CC=CC=C1)[Si](C)(C)C(C)(C)C3351.4Standard polar33892256
Nepafenac,3TBDMS,isomer #1CC(C)(C)[Si](C)(C)NC1=C(CC(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=CC=C1C(=O)C1=CC=CC=C13227.5Semi standard non polar33892256
Nepafenac,3TBDMS,isomer #1CC(C)(C)[Si](C)(C)NC1=C(CC(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=CC=C1C(=O)C1=CC=CC=C13287.7Standard non polar33892256
Nepafenac,3TBDMS,isomer #1CC(C)(C)[Si](C)(C)NC1=C(CC(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=CC=C1C(=O)C1=CC=CC=C13241.8Standard polar33892256
Nepafenac,3TBDMS,isomer #2CC(C)(C)[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C3171.0Semi standard non polar33892256
Nepafenac,3TBDMS,isomer #2CC(C)(C)[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C3192.8Standard non polar33892256
Nepafenac,3TBDMS,isomer #2CC(C)(C)[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C3179.0Standard polar33892256
Nepafenac,4TBDMS,isomer #1CC(C)(C)[Si](C)(C)N(C(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C3473.8Semi standard non polar33892256
Nepafenac,4TBDMS,isomer #1CC(C)(C)[Si](C)(C)N(C(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C3477.0Standard non polar33892256
Nepafenac,4TBDMS,isomer #1CC(C)(C)[Si](C)(C)N(C(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C3126.4Standard polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Nepafenac GC-MS (Non-derivatized) - 70eV, Positivesplash10-03di-1490000000-472a61bcbe3904de6ac42017-09-01Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Nepafenac GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Nepafenac GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Experimental LC-MS/MSLC-MS/MS Spectrum - Nepafenac , positive-QTOFsplash10-03dr-1490000000-433d63cd52e5b86417da2017-09-14HMDB team, MONAView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Nepafenac 10V, Positive-QTOFsplash10-0a4r-0190000000-b6c2bf9435ad635d30bf2016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Nepafenac 20V, Positive-QTOFsplash10-0a4r-0890000000-1c148620fd11833346402016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Nepafenac 40V, Positive-QTOFsplash10-0a4i-2900000000-de52c273376f27e1aec82016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Nepafenac 10V, Negative-QTOFsplash10-0udi-0090000000-1410eafe17e767b3cc392016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Nepafenac 20V, Negative-QTOFsplash10-0w2c-3290000000-3604d63c0fc47c406ecc2016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Nepafenac 40V, Negative-QTOFsplash10-0006-9200000000-0ccf405a700b155ba2432016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Nepafenac 10V, Positive-QTOFsplash10-0a4i-0090000000-3060c6f1d3f25782b5f62021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Nepafenac 20V, Positive-QTOFsplash10-06si-0970000000-521792df462056dc05542021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Nepafenac 40V, Positive-QTOFsplash10-004i-9400000000-b292dc56c56def4c3cc12021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Nepafenac 10V, Negative-QTOFsplash10-0ik9-0090000000-db943419dc26289ab4fe2021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Nepafenac 20V, Negative-QTOFsplash10-03di-0090000000-409cecc16290d2050d372021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Nepafenac 40V, Negative-QTOFsplash10-0006-9540000000-5ae94d44ecaaabdcabf92021-10-11Wishart LabView Spectrum
Biological Properties
Cellular Locations
  • Cytoplasm
  • Membrane
Biospecimen Locations
  • Blood
  • Urine
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB06802 details
UrineExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB06802 details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDDB06802
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID133160
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkNepafenac
METLIN IDNot Available
PubChem Compound151075
PDB IDNot Available
ChEBI ID75922
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000 Aug;24(4):357-70. [PubMed:10850857 ]
  2. Ke TL, Graff G, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000 Aug;24(4):371-84. [PubMed:10850858 ]
  3. Lane SS, Modi SS, Lehmann RP, Holland EJ: Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg. 2007 Jan;33(1):53-8. [PubMed:17189793 ]
  4. Walters T, Raizman M, Ernest P, Gayton J, Lehmann R: In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007 Sep;33(9):1539-45. [PubMed:17720067 ]
  5. Bucci FA Jr, Waterbury LD: Re: Pharmacokinetics and pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2008 Aug;34(8):1226; author reply 1226-7. doi: 10.1016/j.jcrs.2008.05.019. [PubMed:18655957 ]
  6. Summary Basis of Decision (SBD): NEVANAC. [Link]

Enzymes

General function:
Involved in peroxidase activity
Specific function:
Mediates the formation of prostaglandins from arachidonate. May have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity.
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular weight:
68995.625
References
  1. Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000 Aug;24(4):357-70. [PubMed:10850857 ]
General function:
Involved in peroxidase activity
Specific function:
May play an important role in regulating or promoting cell proliferation in some normal and neoplastically transformed cells.
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular weight:
68685.82
References
  1. Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000 Aug;24(4):357-70. [PubMed:10850857 ]